Inflammx Therapeutics, Inc.

Inflammx Therapeutics, Inc. is a dynamic pharmaceutical manufacturing company focused on pioneering advancements in the treatment of autoinflammatory diseases. Located in Tampa, FL, with an additional location in San Diego, CA, Inflammx Therapeutics is dedicated to modulating inflammasome-mediated autoinflammation, particularly in ophthalmology, nephropathy, and neurodegenerative diseases.

Inflammx Therapeutics, Inc. is at the forefront of developing an orally administered compound designed to inhibit the dysregulated NLRP3 Inflammasome pathway. This innovative approach targets conditions such as Diabetic Macular Edema (DME) secondary to Diabetic Retinopathy (DR), Chronic Kidney Disease secondary to Diabetic Nephropathy (DN), and the Intermediate form of Age-Related Macular Degeneration (AMD). With a Phase 2 asset (Xiflam) poised for clinical trials, Inflammx Therapeutics is committed to transforming patient care through groundbreaking research and development. The primary address for Inflammx Therapeutics, Inc. is Tampa, FL 33606, US.

At Inflammx Therapeutics, Inc., the objective is clear: disease modification through the normalization of pathological prematurely open hemichannels in the cell membrane. By inhibiting the dysregulated NLRP3 Inflammasome, Inflammx Therapeutics aims to reduce inflammation and promote tissue regeneration. We invite the manager of Inflammx Therapeutics, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight your innovative work.